CIA Memo Reveals Gottlieb's Dismissal of COVID-19 Seroprevalence Studies
A newly released memo from the Central Intelligence Agency (CIA) reveals that Dr. Scott Gottlieb, who is both a former commissioner of the Food and Drug Administration (FDA) and a board member at Pfizer, dismissed findings from two significant California studies on COVID-19 seroprevalence. These studies suggested that the actual number of infections in California was much higher than the confirmed cases reported at the time. This disclosure raises important questions about the guidance provided to intelligence officials during the early stages of the pandemic.
Gottlieb confirmed that the briefing occurred but noted that CIA officials were aware of his affiliation with Pfizer. Neither the CIA, the FDA, nor Pfizer responded to requests for comments regarding this matter. The memo serves as a summary of the briefing rather than a verbatim account, which may limit the accuracy of the statements attributed to Gottlieb. According to the memo, while Gottlieb acknowledged that infections were likely undercounted, he rejected the extent suggested by the California studies, estimating the national seroprevalence at 20% to 25%.
The seroprevalence studies in question were part of a broader effort to assess the true scale of the pandemic. One study focused on antibody prevalence in Santa Clara County, while another examined Los Angeles County. Both studies indicated that infection rates were significantly higher than the number of confirmed cases, suggesting that a substantial portion of the population had already been exposed to the virus. These findings were consistent with other seroprevalence research conducted across the United States during the same timeframe.
Gottlieb's estimate of 20% to 25% for national seroprevalence aligned with some national modeling efforts. A study published in May 2020, which utilized influenza surveillance networks to estimate state-specific prevalence of SARS-CoV-2, supported the idea that the virus was more widespread than the confirmed case counts suggested. However, the memo indicates that Gottlieb argued this level of exposure was insufficient for achieving herd immunity, a claim that would later influence discussions surrounding the necessity of mass vaccination campaigns.
Investigative journalist Sonia Elijah remarked that the briefing exemplified a pattern of treating confirmed cases as the primary measure of risk, which kept the public vulnerable and made vaccines appear essential. Her comments underscore a recurring criticism of public health messaging during the pandemic: that officials and corporate executives with financial interests in pharmaceutical products may have shaped policy in ways that prioritized vaccine sales over accurate risk communication.
Gottlieb's dual roles as a Pfizer board member and a former FDA commissioner raise potential conflict of interest concerns that were not disclosed in the briefing memo. However, since the memo is an agency summary rather than a direct transcript, it may not accurately reflect Gottlieb's exact words. This limitation is significant because the phrasing of his dismissal of the California studies could have been influenced by the note-taker's interpretation.
Implications of Gottlieb's Advisory Role
Despite this, the existence of the memo offers a rare insight into the private discussions of public health officials during the pandemic. While it does not definitively prove that Gottlieb's advice directly led to the decision to pursue mass vaccination, it highlights the involvement of an executive with financial ties to Pfizer advising the CIA during the early pandemic. This relationship raises concerns about the influence of pharmaceutical companies on government decision-making.
Critics have pointed to the rapid development and approval of COVID-19 vaccines as evidence that public health agencies may have prioritized corporate interests over independent scientific scrutiny. The dismissal of seroprevalence data also has implications for public trust. If officials knowingly minimized the true infection rate, they may have contributed to policies that did not accurately reflect the actual risk to the public.
Research published during the pandemic has emphasized the difficulties in standardizing seroprevalence assays, complicating efforts to compare results across studies. Nevertheless, consistent findings across multiple studies suggested that the virus was indeed more widespread than official counts indicated.
Filed & Cleared
The CIA memo adds a new layer to the historical record of the COVID-19 pandemic, illustrating how senior figures with ties to the pharmaceutical industry interacted with intelligence agencies. While the memo does not establish a direct causal link between Gottlieb's statements and subsequent policy decisions, it underscores the necessity for transparency in public health decision-making. The American public deserves full disclosure of the factors that influenced pandemic responses, including any potential conflicts of interest among advisors.
This episode serves as a reminder that early pandemic data was subject to interpretation and that the decisions made by officials had significant consequences. As more documents are released, a clearer understanding may emerge regarding how the interplay between corporate interests and government policy shaped the course of the pandemic. For now, the memo stands as a document that warrants continued scrutiny from journalists, researchers, and the public.
